EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Germ Cell Tumors: A Single-Center Experience

Kameliya Kostadinova, Krasen Venkov, Ivan Tonev, Milcho Mincheff, Andriyana Bankova, Georgi Mihaylov

Uro · 20.07.2026 · 6 (3) · 20

DOI: 10.3390/uro6030020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Uro, online erschienen am 20.07.2026. Verfasst von Kameliya Kostadinova und 5 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) is an established salvage therapy for relapsed or refractory (R/R) germ cell tumors (GCTs).

Methods

We conducted a retrospective analysis of 9 patients (23–41 years of age) with relapsed/refractory (R/R) GCTs treated according to the Swedish–Norwegian Testicular Cancer Group Clinical Protocol (SWENOTECA), at the Specialized Hospital for Active Treatment of Hematological Diseases (SHATHD) in Sofia, Bulgaria. The study evaluates the efficacy and safety of HDCT followed by ASCT in R/R GCTs eligible for second-line consolidation. The cohort was predominantly high-risk, with 77.7% of patients exhibiting stable or progressive disease (SD/PD) after first-line platinum therapy. Response was assessed via RECIST 1.1 criteria and tumor marker monitoring.

Results

Median OS and PFS were 8.4 and 5.9 months, respectively. While the ORR post-ASCT was 33.3% (all CR), the 2-year survival plateau (33.3%) suggests curative potential in a subset of patients. Notably, there was no treatment-related mortality (TRM).

Conclusions

Tandem HDCT is a feasible salvage strategy with manageable toxicity and no TRM in this small, heavily pre-treated cohort. Although efficacy results are exploratory due to the limited number of patients, the observed long-term remissions confirm the curative potential of this standard-of-care consolidation in a real-world clinical setting.

Zitieren

APA

Kostadinova, K., Venkov, K., Tonev, I., Mincheff, M., Bankova, A., & Mihaylov, G. (2026). Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Germ Cell Tumors: A Single-Center Experience. Uro, 6(3), 20. https://doi.org/10.3390/uro6030020

Vancouver

Kostadinova K, Venkov K, Tonev I, Mincheff M, Bankova A, Mihaylov G. Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Germ Cell Tumors: A Single-Center Experience. Uro. 2026;6(3):20. doi:10.3390/uro6030020

BibTeX
@article{Kostadinova2026,
  author = {Kostadinova, Kameliya and Venkov, Krasen and Tonev, Ivan and Mincheff, Milcho and Bankova, Andriyana and Mihaylov, Georgi},
  title = {Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Germ Cell Tumors: A Single-Center Experience},
  journal = {Uro},
  year = {2026},
  volume = {6},
  number = {3},
  pages = {20},
  doi = {10.3390/uro6030020}
}
Kostenlos starten →